Gubra A/S announced a collaboration with Amylyx (AMLX) Pharmaceuticals for the development of a potential novel long-acting GLP-1 receptor antagonist. “We are pleased to partner with Amylyx to advance GLP-1 receptor antagonism research. This collaboration and development agreement is an example of leading pharmaceutical companies partnering with us for our machine learning-based peptide drug discovery platform. … Gubra and Amylyx anticipate identifying a lead development candidate to enter Investigational New Drug or IND -enabling studies. Amylyx then has the option to lead development once the drug peptide therapeutic has been identified. Under the agreement, Gubra will receive upfront and research payments and may receive more than $50M in success-based development and commercialization milestones plus mid-single digit royalties on worldwide net sales. “As we continue to develop our pipeline, we seek ways to innovate continually to improve care for those in need,” said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. “The GLP-1 receptor is a well-characterized biological target and one of the key regulators of the glucose insulin response. Given the highly significant data avexitide, our first-in-class GLP-1 receptor antagonist, has generated to date, we are excited to further explore this known pathway and the potential of adding to our pipeline a new long-acting GLP-1 receptor antagonist,” said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMLX:
- Amylyx Partners with Gubra for GLP-1 Antagonist
- Amylyx announces design of LUCIDITY clinical trial
- Amylyx upgraded to Outperform from Neutral at Baird
- Amylyx price target raised to $12 from $8 at H.C. Wainwright
- Amylyx Pharmaceuticals Q3 2024 Financial Highlights
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
